20P Health-related quality of life in patients previously treated with an EGFR-TKI from HARMONi: A phase III trial of ivonescimab vs placebo plus chemotherapy

Ivonescimab (IVO) is a programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF) bispecific antibody. IVO + chemotherapy (CT) showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and increased overall survival (OS) compared to placebo (PBO) + CT in patients (pts) with advanced or metastatic epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who progressed on or following EGFR-tyrosine kinase inhibitor (TKI) treatment.